000623 吉林敖东
已收盘 08-11 15:00:00
资讯
新帖
简况
吉林敖东:已于2025年4月21日审议实施《市值管理制度》和《估值提升计划》
证券之星 · 08-09 17:21
吉林敖东:已于2025年4月21日审议实施《市值管理制度》和《估值提升计划》
吉林敖东:广发证券股权投资是公司优质核心金融资产
证券之星 · 08-06
吉林敖东:广发证券股权投资是公司优质核心金融资产
吉林敖东:广发证券股权投资是公司优质核心金融资产
证券之星 · 08-04
吉林敖东:广发证券股权投资是公司优质核心金融资产
吉林敖东:安神补脑液在制备防治阿尔茨海默病药物中的应用
证券之星 · 08-04
吉林敖东:安神补脑液在制备防治阿尔茨海默病药物中的应用
股市必读:吉林敖东新发布《吉林敖东药业集团股份有限公司股东股份质押的公告》
证券之星 · 08-03
股市必读:吉林敖东新发布《吉林敖东药业集团股份有限公司股东股份质押的公告》
吉林敖东(000623)披露股东股份质押公告,7月31日股价上涨0.38%
证券之星 · 07-31
吉林敖东(000623)披露股东股份质押公告,7月31日股价上涨0.38%
吉林敖东(000623)股东敦化市金诚实业有限责任公司质押980万股,占总股本0.82%
证券之星 · 07-31
吉林敖东(000623)股东敦化市金诚实业有限责任公司质押980万股,占总股本0.82%
吉林敖东(000623)披露2026年第一次临时股东大会决议公告,7月17日股价下跌3.01%
证券之星 · 07-17
吉林敖东(000623)披露2026年第一次临时股东大会决议公告,7月17日股价下跌3.01%
吉林敖东(000623.SZ)发预增,预计半年度归母净利润19.22亿元-21.79亿元,同比增长50%-70%
智通财经 · 07-14
吉林敖东(000623.SZ)发预增,预计半年度归母净利润19.22亿元-21.79亿元,同比增长50%-70%
吉林敖东(000623)披露2026年第一次临时股东大会提示性公告,7月13日股价下跌0.79%
证券之星 · 07-13
吉林敖东(000623)披露2026年第一次临时股东大会提示性公告,7月13日股价下跌0.79%
股市必读:吉林敖东(000623)7月1日董秘有最新回复
证券之星 · 07-02
股市必读:吉林敖东(000623)7月1日董秘有最新回复
吉林敖东:2025年严格落实《市值管理制度》及估值提升计划
证券之星 · 07-01
吉林敖东:2025年严格落实《市值管理制度》及估值提升计划
6月22日吉林敖东涨7.23%,中药ETF汇添富基金重仓该股
证券之星 · 06-22
6月22日吉林敖东涨7.23%,中药ETF汇添富基金重仓该股
吉林敖东(000623.SZ):左卡尼汀注射液获得药品注册证书
智通财经 · 06-08
吉林敖东(000623.SZ):左卡尼汀注射液获得药品注册证书
吉林敖东(000623)披露控股子公司获得药品补充申请批准通知书,5月20日股价下跌1.12%
中金财经 · 05-20
吉林敖东(000623)披露控股子公司获得药品补充申请批准通知书,5月20日股价下跌1.12%
吉林敖东(000623.SZ):注射用盐酸地尔硫䓬通过仿制药一致性评价
智通财经 · 05-20
吉林敖东(000623.SZ):注射用盐酸地尔硫䓬通过仿制药一致性评价
股市必读:吉林敖东(000623)5月19日披露最新机构调研信息
证券之星 · 05-20
股市必读:吉林敖东(000623)5月19日披露最新机构调研信息
股市必读:吉林敖东(000623)5月18日董秘有最新回复
证券之星 · 05-19
股市必读:吉林敖东(000623)5月18日董秘有最新回复
吉林敖东最新公告:控股子公司药品注射用丁二磺酸腺苷蛋氨酸通过一致性评价
证券之星 · 05-11
吉林敖东最新公告:控股子公司药品注射用丁二磺酸腺苷蛋氨酸通过一致性评价
股市必读:吉林敖东(000623)5月6日董秘有最新回复
证券之星 · 05-07
股市必读:吉林敖东(000623)5月6日董秘有最新回复
加载更多
公司概况
公司名称:
吉林敖东药业集团股份有限公司
所属行业:
医药制造业
上市日期:
1996-10-28
主营业务:
吉林敖东药业集团股份有限公司的主营业务是中药、化学药品的研发、制造与销售。公司的主要产品是安神补脑液、小儿柴桂退热口服液、养血饮口服液、注射用核糖核酸II、肾复康片、血府逐瘀口服液、少腹逐瘀颗粒、龟芪参口服液、注射用盐酸平阳霉素、伸筋片、注射用丁二磺酸腺苷蛋氨酸、金芪降糖胶囊、注射用盐酸地尔硫卓、脑心舒口服液、生脉饮口服液、孕康颗粒、感冒清热胶囊、复方金银花颗粒、羚贝止咳糖浆、利脑心胶囊、维D2乳酸钙片、鼻炎宁颗粒、磷酸奥司他韦胶囊、金莲花口服液、注射用卡络磺钠、杜蛭丸、断血流胶囊。
发行价格:
7.20
{"stockData":{"symbol":"000623","market":"SZ","secType":"STK","nameCN":"吉林敖东","latestPrice":18.08,"timestamp":1786431804000,"preClose":18.28,"halted":0,"volume":13012507,"delay":0,"changeRate":-0.0109,"floatShares":1191000000,"shares":1196000000,"eps":2.2949,"marketStatus":"已收盘","change":-0.2,"latestTime":"08-11 15:00:00","open":18.28,"high":18.42,"low":18.07,"amount":238000000,"amplitude":0.0191,"askPrice":18.08,"askSize":338,"bidPrice":18.07,"bidSize":645,"shortable":0,"etf":0,"ttmEps":2.2949,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":5,"adr":0,"adjPreClose":18.28,"symbolType":"stock","openAndCloseTimeList":[[1786411800000,1786419000000],[1786424400000,1786431600000]],"highLimit":20.11,"lowLimit":16.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1195895387,"isCdr":false,"pbRate":0.69,"roa":"--","peRate":7.878339,"roe":"2.79%","epsLYR":2.0416,"committee":0.242582,"marketValue":21622000000,"turnoverRate":0.0109,"status":1,"floatMarketCap":21534000000},"requestUrl":"/m/hq/s/000623","defaultTab":"news","newsList":[{"id":"2658744606","title":"吉林敖东:已于2025年4月21日审议实施《市值管理制度》和《估值提升计划》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658744606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658744606?lang=zh_cn&edition=full","pubTime":"2026-08-09 17:21","pubTimestamp":1786267264,"startTime":"0","endTime":"0","summary":"证券之星消息,吉林敖东08月09日在投资者关系平台上答复投资者关心的问题。这笔投资收益属于账面浮盈,属于“看得见摸不着”,大规模减持受各种约束,难以直接变现投入主业,造成公司长期深度估值折价。反观吉林敖东手握巨额优质股权,股价表现却长期萎靡。公司已于2025年4月21日,第十一届董事会第十六次会议审议实施《市值管理制度》和《估值提升计划》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900007380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0086","BK0201","BK0188","000623","BK0028","BK0239","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657827634","title":"吉林敖东:广发证券股权投资是公司优质核心金融资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2657827634","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657827634?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:51","pubTimestamp":1786020681,"startTime":"0","endTime":"0","summary":"证券之星消息,吉林敖东08月05日在投资者关系平台上答复投资者关心的问题。广发证券股权投资是公司优质核心金融资产,能够持续为公司带来稳定收益,是夯实公司资本实力、支撑“医药健康+金融资本”双轮驱动发展战略的坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600037547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","LU1934453819.USD","000623","BK0012","BK0183","BK0239","01776","BK0086","SG9999001093.SGD","BK0276","BK1147","LU1979443071.USD","BK0201","000776","BK0074","BK0188","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656834475","title":"吉林敖东:广发证券股权投资是公司优质核心金融资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2656834475","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656834475?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:36","pubTimestamp":1785803771,"startTime":"0","endTime":"0","summary":"目前公司持有广发证券大额股权,每年获得稳定分红现金流。想向公司咨询:1、控股股东层面对于盘活广发证券股权投资有无中长期顶层规划?广发证券股权投资是公司优质核心金融资产,能够持续贡献稳定分红现金流,为医药主业长期稳步发展储备资金,是公司实施产融结合、平衡经营风险的重要布局。公司作为广发证券第一股东,依据相关法律法规、上市公司章程审慎行使股东权利、履行股东义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400007747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0074","BK1564","BK0028","BK0188","BK0276","LU1934453819.USD","000623","SG9999001093.SGD","000776","BK0239","LU1979443071.USD","BK0012","BK1147","BK0201","01776","BK0183","BK0086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656583102","title":"吉林敖东:安神补脑液在制备防治阿尔茨海默病药物中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2656583102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656583102?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:33","pubTimestamp":1785803587,"startTime":"0","endTime":"0","summary":"2025年,公司安神补脑液通过研发获得《安神补脑液在制备防治阿尔茨海默病药物中的应用》《安神补脑液在制备治疗抗衰老药物中的应用》两项发明专利,在此基础上公司将加大安神补脑液在抗衰老、防治阿尔茨海默病方面循证医学及真实世界研究,赋能产品价值提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400007699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0074","BK0012","BK0201","BK0086","BK0028","BK0239","000623"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656934872","title":"股市必读:吉林敖东新发布《吉林敖东药业集团股份有限公司股东股份质押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656934872","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656934872?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:03","pubTimestamp":1785693795,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,吉林敖东报收于18.37元,上涨0.38%,换手率1.19%,成交量14.19万手,成交额2.6亿元。公司公告汇总吉林敖东药业集团股份有限公司股东股份质押的公告吉林敖东药业集团股份有限公司接到股东敦化市金诚实业有限责任公司通知,金诚公司将其持有的9,800,000股公司股份质押给招商证券股份有限公司,占其所持股份比例3.00%,占公司总股本比例0.82%,质押用途为经营业务需要。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0074","BK0188","BK0086","000623","BK0012","BK0028","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655629543","title":"吉林敖东(000623)披露股东股份质押公告,7月31日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655629543","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655629543?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:18","pubTimestamp":1785507519,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,吉林敖东报收于18.37元,较前一交易日上涨0.38%,最新总市值为219.69亿元。近日,吉林敖东药业集团股份有限公司发布股东股份质押公告。公告显示,公司股东敦化市金诚实业有限责任公司将其持有的9,800,000股公司股份质押给招商证券股份有限公司,占其所持股份比例3.00%,占公司总股本比例0.82%,质押用途为经营业务需要。本次质押后,金诚公司累计质押股份144,175,000股,占其所持股份比例44.08%,占公司总股本比例12.06%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100041872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0012","BK0201","BK0239","BK0188","000623","BK0028","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655503303","title":"吉林敖东(000623)股东敦化市金诚实业有限责任公司质押980万股,占总股本0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655503303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655503303?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:29","pubTimestamp":1785493782,"startTime":"0","endTime":"0","summary":"证券之星消息,吉林敖东7月31日公开信息显示,股东敦化市金诚实业有限责任公司向招商证券股份有限公司合计质押980.0万股,占总股本0.82%。质押详情见下表:截止本公告日,股东敦化市金诚实业有限责任公司已累计质押股份1.44亿股,占其持股总数的44.08%。吉林敖东主营业务:主要从事中成药、生物化学药研发、制造和销售。本文数据来源于吉林敖东公告,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100033717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0201","BK0086","000623","BK0188","BK0028","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652860632","title":"吉林敖东(000623)披露2026年第一次临时股东大会决议公告,7月17日股价下跌3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652860632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652860632?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:13","pubTimestamp":1784297599,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,吉林敖东报收于18.06元,较前一交易日下跌3.01%,最新总市值为215.98亿元。该股当日开盘18.56元,最高18.79元,最低17.97元,成交额达3.95亿元,换手率为1.81%。近日,吉林敖东发布《2026年第一次临时股东大会决议公告》。公告显示,公司于2026年7月17日召开2026年第一次临时股东会,审议通过董事会换届选举议案。所有候选人获出席股东所持表决权过半数通过,任期三年。公告指出,会议召集召开程序合法合规,表决结果有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0074","BK0086","BK0012","BK0201","000623","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651179249","title":"吉林敖东(000623.SZ)发预增,预计半年度归母净利润19.22亿元-21.79亿元,同比增长50%-70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651179249","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651179249?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:40","pubTimestamp":1784022005,"startTime":"0","endTime":"0","summary":"智通财经APP讯,吉林敖东(000623.SZ)发布2026年半年度业绩预告,公司预计2026年半年度实现归属于上市公司股东的净利润19.22亿元~21.79亿元,比上年同期增长50%~70%。报告期内,公司聚焦医药主业,践行“专注于人、专精于药”经营理念,持续夯实主营业务经营质量;围绕“大品种群、多品种群”产品推广策略稳步开展市场拓展,坚持“医药健康+金融资本”双轮协同发展模式,统筹推进年度经营规划落地。本期经营业绩同比大幅增长主要原因是公司投资收益同比增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"吉林敖东(000623.SZ)发预增,预计半年度归母净利润19.22亿元-21.79亿元,同比增长50%-70%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000623"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171311","title":"吉林敖东(000623)披露2026年第一次临时股东大会提示性公告,7月13日股价下跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171311","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651171311?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:18","pubTimestamp":1783952305,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘,吉林敖东报收于17.5元,较前一交易日下跌0.79%,最新总市值为209.28亿元。该股当日开盘17.64元,最高17.86元,最低17.46元,成交额达2.26亿元,换手率为1.08%。近日,吉林敖东药业集团股份有限公司发布《关于召开2026年第一次临时股东会的提示性公告》。公告显示,公司将于2026年7月17日召开2026年第一次临时股东会,会议采取现场投票与网络投票相结合的方式,股权登记日为2026年7月10日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300040156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0074","BK0028","BK0188","000623","BK0239","BK0012","BK0201","BK0086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648540482","title":"股市必读:吉林敖东(000623)7月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648540482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648540482?lang=zh_cn&edition=full","pubTime":"2026-07-02 01:32","pubTimestamp":1782927131,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,吉林敖东报收于18.71元,上涨5.53%,换手率2.39%,成交量28.43万手,成交额5.25亿元。同时积极运用市场化工具,2020年至2025年累计投入11.4亿元完成四次股份回购,合计回购6,868万股,2024年已完成4,517万股股份注销,有效优化股本结构、提振市场信心。公司公告汇总:吉林敖东发布2025年度分红派息实施公告,每股派息0.30元(含税),股权登记日为2026年7月7日,除权除息日为2026年7月8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200000895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000623","BK0188","BK0028","BK0201","BK0012","BK0086","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648543095","title":"吉林敖东:2025年严格落实《市值管理制度》及估值提升计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2648543095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648543095?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:53","pubTimestamp":1782910410,"startTime":"0","endTime":"0","summary":"证券之星消息,吉林敖东07月01日在投资者关系平台上答复投资者关心的问题。2025年,公司严格落实《市值管理制度》及估值提升计划,多措并举稳定市值、维护全体股东权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100041241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","000623","BK0074","BK0012","BK0239","BK0086","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645968040","title":"6月22日吉林敖东涨7.23%,中药ETF汇添富基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645968040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645968040?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:42","pubTimestamp":1782117744,"startTime":"0","endTime":"0","summary":"证券之星消息,6月22日吉林敖东涨7.23%,收盘报18.39元,换手率2.22%,成交量26.48万手,成交额4.75亿元。重仓吉林敖东的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为汇添富基金的中药ETF汇添富。中药ETF汇添富的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200023697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0028","BK0239","BK0188","560080","BK0012","000623","BK0201","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641010254","title":"吉林敖东(000623.SZ):左卡尼汀注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2641010254","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641010254?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:14","pubTimestamp":1780906497,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 吉林敖东(000623.SZ)发布公告,近日,公司股子公司吉林敖东药业集团延吉股份有限公司(以下简称“延吉药业”)收到国家药品监督管理局下发的“左卡尼汀注射液”的《药品注册证书》。本次公司控股子公司延吉药业获得左卡尼汀注射液的《药品注册证书》,完善了公司的产品结构,进一步丰富了公司产品种类,增强了公司核心竞争力,为公司稳步发展创造了有利条件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"吉林敖东(000623.SZ):左卡尼汀注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","000623","BK0239","BK0086","BK0074","BK0201","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030848","title":"吉林敖东(000623)披露控股子公司获得药品补充申请批准通知书,5月20日股价下跌1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030848","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636030848?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:53","pubTimestamp":1779270826,"startTime":"0","endTime":"0","summary":"近日,吉林敖东药业集团股份有限公司披露《关于控股子公司获得药品补充申请批准通知书的自愿性信息披露公告》。公告显示,公司控股子公司吉林敖东药业集团延吉股份有限公司收到国家药品监督管理局下发的“注射用盐酸地尔硫”《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价,同时同意变更处方和生产工艺、药品质量标准、直接接触药品的包装材料和容器,并修订说明书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260520/32239991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0201","BK0012","BK0086","BK0028","BK0074","000623","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636955814","title":"吉林敖东(000623.SZ):注射用盐酸地尔硫䓬通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2636955814","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636955814?lang=zh_cn&edition=full","pubTime":"2026-05-20 15:57","pubTimestamp":1779263843,"startTime":"0","endTime":"0","summary":"智通财经APP讯,吉林敖东(000623.SZ)发布公告,近日,公司控股子公司吉林敖东药业集团延吉股份有限公司(简称“延吉药业”)收到国家药品监督管理局下发的“注射用盐酸地尔硫䓬”的《药品补充申请批准通知书》。据悉,注射用盐酸地尔硫䓬通过仿制药质量和疗效一致性评价,适用于室上性心动过速、手术时异常高血压的急救处置、高血压急症、不稳定心绞痛症状。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0086","BK0028","BK0239","BK0188","BK0012","000623","BK0201","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636865200","title":"股市必读:吉林敖东(000623)5月19日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2636865200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636865200?lang=zh_cn&edition=full","pubTime":"2026-05-20 01:55","pubTimestamp":1779213312,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘,吉林敖东报收于17.86元,上涨0.51%,换手率0.73%,成交量8.7万手,成交额1.55亿元。来自机构调研要点:公司2020年至2025年累计投入11.4亿元回购股份,共回购6,868万股,持续彰显对股东回报的重视。2020年至2025年期间,公司累计使用11.4亿元实施四次股份回购,合计回购股份6,868万股;其中2024年至2025年完成回购资金4.2亿元,回购股份2,351.38万股;2024年已注销回购股份4,517万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000001515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0012","BK0086","BK0201","BK0239","000623","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636600867","title":"股市必读:吉林敖东(000623)5月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636600867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636600867?lang=zh_cn&edition=full","pubTime":"2026-05-19 01:20","pubTimestamp":1779124817,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘,吉林敖东报收于17.77元,下跌1.82%,换手率0.99%,成交量11.77万手,成交额2.1亿元。董秘最新回复投资者: 近日有投资者在东方财富股吧发布“吉林敖东创新药转型方案”的文章。文章详细分析了吉林敖东创新转型的优劣势并提供了一套完整的方案。公司主营业务营收持续下滑,持续亏损,创新转型已迫在眉睫。2025年,公司陆续获得化药批准文号8个及化药原料药1个,获得中药批准文号4个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900001883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","BK0012","BK0201","BK0239","BK0188","000623","BK0028","BK0074"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634886382","title":"吉林敖东最新公告:控股子公司药品注射用丁二磺酸腺苷蛋氨酸通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2634886382","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634886382?lang=zh_cn&edition=full","pubTime":"2026-05-11 18:51","pubTimestamp":1778496690,"startTime":"0","endTime":"0","summary":"吉林敖东(000623.SZ)公告称,公司控股子公司延吉药业收到国家药监局下发的“注射用丁二磺酸腺苷蛋氨酸”《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价,适用于肝硬化前和肝硬化所致肝内胆汁淤积及妊娠期肝内胆汁淤积。本次获批有利于扩大市场份额,但预计短期内不会对公司业绩产生重大影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100028929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0074","BK0012","BK0201","BK0086","BK0028","BK0239","000623"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633153824","title":"股市必读:吉林敖东(000623)5月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2633153824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633153824?lang=zh_cn&edition=full","pubTime":"2026-05-07 01:40","pubTimestamp":1778089219,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,吉林敖东报收于19.0元,上涨0.69%,换手率1.31%,成交量15.62万手,成交额2.97亿元。董秘最新回复投资者: 董秘您好,目前公司二级市场市场关注度与机构持仓活跃度一般,请问公司是否计划主动开展机构沟通工作,通过投资者路演、线上线下调研、专项交流等方式,向公募、私募等机构传递公司经营基本面、业务布局及长期成长逻辑,提升机构认可度与配置意愿?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700001175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0074","BK0086","BK0012","BK0201","000623","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786455738695,"stockEarnings":[{"period":"1week","weight":-0.0027},{"period":"1month","weight":0.0363},{"period":"3month","weight":-0.0157},{"period":"6month","weight":-0.0167},{"period":"1year","weight":-0.0203},{"period":"ytd","weight":-0.0485}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":-0.0074},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.04},{"period":"1year","weight":0.0912},{"period":"ytd","weight":-0.0006}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"吉林敖东药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63885人(较上一季度增加3.56%)","perCapita":"18643股","listingDate":"1996-10-28","address":"吉林省延边朝鲜族自治州敦化市敖东大街2158号","registeredCapital":"119589万元","survey":" 吉林敖东药业集团股份有限公司的主营业务是中药、化学药品的研发、制造与销售。公司的主要产品是安神补脑液、小儿柴桂退热口服液、养血饮口服液、注射用核糖核酸II、肾复康片、血府逐瘀口服液、少腹逐瘀颗粒、龟芪参口服液、注射用盐酸平阳霉素、伸筋片、注射用丁二磺酸腺苷蛋氨酸、金芪降糖胶囊、注射用盐酸地尔硫卓、脑心舒口服液、生脉饮口服液、孕康颗粒、感冒清热胶囊、复方金银花颗粒、羚贝止咳糖浆、利脑心胶囊、维D2乳酸钙片、鼻炎宁颗粒、磷酸奥司他韦胶囊、金莲花口服液、注射用卡络磺钠、杜蛭丸、断血流胶囊。","listedPrice":7.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉林敖东(000623)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉林敖东(000623)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉林敖东,000623,吉林敖东股票,吉林敖东股票老虎,吉林敖东股票老虎国际,吉林敖东行情,吉林敖东股票行情,吉林敖东股价,吉林敖东股市,吉林敖东股票价格,吉林敖东股票交易,吉林敖东股票购买,吉林敖东股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉林敖东(000623)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉林敖东(000623)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}